ArticleScience progress
Dapagliflozin attenuates nicotine-induced apoptosis by targeting the ASK1/p38/JNK apoptotic pathway in HK-2 cells.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the causal relationship between plasma proteins and obstructive sleep apnea: a study using genome-wide Mendelian randomization, single-cell RNA sequencing analysis, and network pharmacology.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveCigarette smoking accelerates kidney disease progression. Emerging evidence suggests that dapagliflozin (DAPA) exerts protective effects against various kidney injuries. This study aimed to investigate the effects of DAPA on nicotine (NIC)-induced apoptosis in human kidney proximal tubular epithelial (HK-2) cells.MethodsHK-2 cells were treated with NIC, DAPA or selective mitogen-activated protein kinase (MAPK) inhibitors (SP600125 and SB203580). Cell viability, apoptotic cell death and reactive oxygen species (ROS), namely intracellular ROS and MitoSOX, were assessed using a CCK-8 assay and flow cytometry. The concentrations of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) were determined by enzyme-linked immunosorbent assay. Protein expression levels related to mitochondrial function, endoplasmic reticulum (ER) stress and the MAPK signalling pathway were analysed by immunoblotting.ResultsDapagliflozin and MAPK inhibitors significantly attenuated NIC-induced apoptosis and improved HK-2 cell viability, as evidenced by increased Bcl-2 expression and decreased Bax and Caspase-3 expression. Apoptosis attenuation was closely associated with the suppression of p-ASK1/p-JNK/p-p38 MAPKs and p-MEK3/p-MEK4 activation. Dapagliflozin and MAPK attenuations regulate the expression of oxidant and antioxidant proteins, reducing intracellular ROS and MitoSOX overproduction and thereby alleviating mitochondrial dysfunction and ER stress. Both agents also significantly reduced pro-inflammatory cytokine levels, including TNF-α and IL-1β.ConclusionsThese findings suggest that DAPA protects HK-2 cells from NIC-induced apoptosis by modulating the ASK1/p38/JNK MAPK signalling pathway, reducing oxidative stress and alleviating inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.